| Clinical data | |
|---|---|
| Other names | BU-LAD; BULAD; 6-Butyl-6-nor-LSD; 6-Butyl-6-nor-Lysergic acid diethylamide |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H31N3O |
| Molar mass | 365.521 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
BU-LAD, also known as 6-butyl-6-nor-LSD or 6-butyl-6-nor-lysergic acid diethylamide, is a psychedelic drug and analogue of lysergic acid diethylamide (LSD) first described by David E. Nichols and colleagues in the 1980s.
According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), BU-LAD is a psychedelic drug similar to LSD, but is significantly less potent than LSD, with a dose of 500 μg orally producing only mild effects.
BU-LAD substitutes for LSD in rodent drug discrimination tests. However, it has 13-fold reduced potency relative to LSD itself and 37- to 42-fold lower potency than ETH-LAD and AL-LAD in this test.
Analogues of BU-LAD include LSD, ETH-LAD, PRO-LAD, AL-LAD, PARGY-LAD, and MAL-LAD, among others.
TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats [...]
| Ergolines (incl. lysergines) |
|
|---|---|
| Clavines (6,8-dimethylergolines) | |
| Lysergamides (lysergic acid amides) |
|
| Ergopeptines (peptide ergolines) |
|
| Partial ergolines |
|
| Related compounds | |
| Natural sources |
|